EU Solicits Stakeholder Views On Fairness And Structure Of EMA’s Fee System
Executive Summary
Stakeholders finally have a chance to air their views about the European Medicine Agency’s fee and remuneration system, particularly whether it is “fair, cost-based and not unduly complex.”
You may also be interested in...
Keep It Simple: EU Consults On Future Design Of EMA’s Fee System
Following a report that identified several shortcomings of the European Medicines Agency fee system, the European Commission has suggested various options to make it sustainable and future-proof.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.